Sherlock Biosciences
Sherlock Biosciences raises $220M Series C at $1.5B valuation
Sherlock Biosciences: Series C Funding Round
Sherlock Biosciences has successfully raised $220M in Series C funding, reaching a valuation of $1.5B.
Company Overview
CRISPR-powered diagnostics
Funding Details
The Series C round was led by Vivo Capital, with participation from Baillie Gifford, GV, Taiho Ventures, Perceptive Advisors, William K. Warren Foundation.
Company Information
- Headquarters: 201 Brookline Avenue, Boston, MA 02215
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Sherlock Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Vivo Capital: Verified investor in Series C
- Baillie Gifford: Verified investor in Series C
- GV: Verified investor in Series C
- Taiho Ventures: Verified investor in Series C
- Perceptive Advisors: Verified investor in Series C
- William K. Warren Foundation: Verified investor in Series C
Company Info
Investors (6)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free